Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 24681954
Sato T, et al. (2015) The TRIM-FLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKC-mediated signaling pathway. Oncogene 34, 1280-91 24681954
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) decrease TRIM45 siRNA increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) decrease TRIM45 siRNA increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) decrease TRIM45 siRNA increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) decrease TRIM45 siRNA increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) no change compared to control TRIM45 siRNA - no change
serum TRIM45 (human) decrease TRIM45 siRNA increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) no change compared to control TRIM45 siRNA - no change
serum TRIM45 (human) decrease TRIM45 siRNA increase

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) no change compared to control TRIM45 siRNA - no change
serum TRIM45 (human) decrease TRIM45 siRNA increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum TRIM45 (human) no change compared to control TRIM45 siRNA - no change
serum TRIM45 (human) decrease TRIM45 siRNA increase

S218-p - MEK1 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human

S222-p - MEK1 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human

S222-p - MEK2 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human

S226-p - MEK2 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human